Precipio, Inc. (PRPO)
NASDAQ: PRPO · Real-Time Price · USD
19.96
-2.17 (-9.81%)
Nov 16, 2026, 4:00 PM EST - Market closed

Precipio Earnings Call Transcripts

Fiscal Year 2026

  • Q3 revenue was $7.2M, product revenue topped $1M, and adjusted EBITDA was ~$400K. Management targets a combined annualized revenue run rate above $40M exiting 2027, supported by commercial expansion and existing infrastructure.

  • Q2 revenue exceeded $7M, up 22% YoY, while adjusted EBITDA turned positive and operating cash flow lifted cash to $3M without financing. Product revenue hit a record, and H2 focus is pipeline conversion and sustained operating leverage.

  • Profitability was achieved in Q3 2025, driven by a unique, rapid diagnostic platform and a shift toward high-margin products. The company targets significant market share in blood cancers, leveraging distributor partnerships and a scalable business model, with no customer attrition to date.

  • AGM 2026

    Shareholders approved the re-election of three directors for three-year terms and ratified the appointment of the independent auditor for 2026. All proposals passed, with results to be filed with the SEC.

  • Q1 2026 revenue was flat sequentially but up 30% year-over-year, with pathology growth offset by product shipment timing and an 8% CMS reimbursement cut. Commercial pipeline expanded to $10M, and margins are expected to recover as investments yield results.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021